ONO-4053 Phase 2a study
Phase 2
- Conditions
- seasonal allergic rhinitis (Japanese cedar pollinosis)
- Registration Number
- JPRN-jRCT2080222655
- Lead Sponsor
- ONO PHARMACEUTICAL CO.,LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
1. patients with seasonal allergic rhinitis (Japanese cedar pollinosis)
Exclusion Criteria
1. Has a disease which may influence the efficacy evaluation (e.g. acute rhinitis)
2. Has or had a history of an allergic drug reaction
3. If female, are pregnant or breastfeeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method nasal symptom score
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does ONO-4053 target in Japanese cedar pollinosis pathophysiology?
How does ONO-4053's efficacy compare to standard antihistamines in seasonal allergic rhinitis trials?
Which biomarkers correlate with ONO-4053 treatment response in Th2-driven allergic rhinitis subtypes?
What safety concerns emerged in ONO PHARMACEUTICAL's Phase 2a ONO-4053 trial for allergic rhinitis?
Are there combination therapies involving ONO-4053 for IgE-mediated allergic diseases under investigation?